Browse by Journal Title

2022

Targeted analysis of cell-free circulating tumor DNA is suitable for early relapse and actionable target detection in patients with neuroblastoma.
Lodrini, M., Graef, J., Thole-Kliesch, T.M., Astrahantseff, K., Sprüssel, A., Grimaldi, M., Peitz, C., Linke, R.B., Hollander, J.F., Lankes, E., Künkele, A., Oevermann, L., Schwabe, G., Fuchs, J., Szymansky, A., Schulte, J.H., Hundsdoerfer, P., Eckert, C., Amthauer, H., Eggert, A. and Deubzer, H.E.
Clinical Cancer Research 28 (9): 1809-1820. 1 May 2022

2021

Early response to first-line anti-PD-1 treatment in Hodgkin lymphoma: a PET-based analysis from the prospective, randomized phase II NIVAHL trial.
Voltin, C.A., Mettler, J., van Heek, L., Goergen, H., Müller, H., Baues, C., Keller, U., Meissner, J., Trautmann-Grill, K., Kerkhoff, A., Fuchs, M., Sasse, S., von Tresckow, B., Dietlein, M., Borchmann, P., Engert, A., Kobe, C. and Bröckelmann, P.J.
Clinical Cancer Research 27 (2): 402-407. January 2021

2018

Targeting Merkel cell carcinoma by engineered T cells specific to T-antigens of Merkel cell polyomavirus.
Gavvovidis, I., Leisegang, M., Willimsky, G., Miller, N.J., Nghiem, P. and Blankenstein, T.
Clinical Cancer Research 24 (15): 3644-3655. August 2018

2017

T cell receptors for clinical therapy: in vitro assessment of toxicity risk.
Kunert, A., Obenaus, M., Lamers, C.H.J., Blankenstein, T. and Debets, R.
Clinical Cancer Research 23 (20): 6012-6020. 15 October 2017

2016

Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors.
Ortiz-Cuaran, S., Scheffler, M., Plenker, D., Dahmen, L., Scheel, A.H., Fernandez-Cuesta, L., Meder, L., Lovly, C.M., Persigehl, T., Merkelbach-Bruse, S., Bos, M., Michels, S., Fischer, R., Albus, K., König, K., Schildhaus, H.U., Fassunke, Jana, Ihle, M.A., Pasternack, H., Heydt, C., Becker, C., Altmüller, J., Ji, H., Müller, C., Florin, A., Heuckmann, J.M., Nuernberg, P., Ansén, S., Heukamp, L.C., Berg, J., Pao, W., Peifer, M., Buettner, R., Wolf, J., Thomas, R.K. and Sos, M.L.
Clinical Cancer Research 22 (19): 4837-4847. 2 October 2016

Eradication of large solid tumors by gene therapy with a T cell receptor targeting a single cancer-specific point mutation.
Leisegang, M., Engels, B., Schreiber, K., Yew, P.Y., Kiyotani, K., Idel, C., Arina, A., Duraiswamy, J., Weichselbaum, R.R., Uckert, W., Nakamura, Y. and Schreiber, H.
Clinical Cancer Research 22 (11): 2734-2743. 1 June 2016

MACC1 induces tumor progression in transgenic mice and colorectal cancer patients via increased pluripotency markers Nanog and Oct4.
Lemos, C., Hardt, M.S., Juneja, M., Voss, C., Foerster, S., Jerchow, B., Haider, W., Blaker, H. and Stein, U.
Clinical Cancer Research 22 (11): 2812-2824. 1 June 2016

Targeting MYCN-driven transcription by BET-bromodomain inhibition.
Henssen, A., Althoff, K., Odersky, A., Beckers, A., Koche, R., Speleman, F., Schäfers, S., Bell, E., Nortmeyer, M., Westermann, F., De Preter, K., Florin, A., Heukamp, L., Spruessel, A., Astrahanseff, K., Lindner, S., Sadowski, N., Schramm, A., Astorgues-Xerri, L., Riveiro, M.E., Eggert, A., Cvitkovic, E. and Schulte, J.H.
Clinical Cancer Research 22 (10): 2470-2481. May 2016

2015

The prognostic impact of CD163-positive macrophages in follicular lymphoma: a study from the BC Cancer Agency and the Lymphoma Study Association.
Kridel, R., Xerri, L., Gelas-Dore, B., Tan, K., Feugier, P., Vawda, A., Canioni, D., Farinha, P., Boussetta, S., Moccia, A.A., Brice, P., Chavez, E.A., Kyle, A.H., Scott, D.W., Sanders, A.D., Fabiani, B., Slack, G.W., Minchinton, A.I., Haioun, C., Connors, J.M., Sehn, L.H., Steidl, C., Gascoyne, R.D. and Salles, G.
Clinical Cancer Research 21 (15): 3428-3435. August 2015

2014

Identification of differentially expressed long noncoding RNAs in bladder cancer.
Peter, S., Borkowska, E., Drayton, R.M., Rakhit, C.P., Noon, A.P., Chen, W. and Catto, J.W.F.
Clinical Cancer Research 20 (20): 5311-5321. 15 October 2014

2013

PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation - a possible target for ATRA response in AML without t(15;17).
Bullinger, L., Schlenk, R.F., Götz, M., Botzenhardt, U., Hofmann, S., Russ, A.C., Babiak, A., Zhang, L., Schneider, V., Döhner, K., Schmitt, M., Döhner, H. and Greiner, J.
Clinical Cancer Research 19 (9): 2562-71. 1 May 2013

Synergistic activity of bortezomib and HDACis in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT and NF-κB.
Bastian, L., Hof, J., Pfau, M., Fichtner, I., Eckert, C., Henze, G., Prada, J., von Stackelberg, A., Seeger, K. and Shalapour, S.
Clinical Cancer Research 19 (6): 1445-1457. 15 March 2013

Molecular pathways: comparing the effects of drugs and T cells to effectively target oncogenes.
Anders, K. and Blankenstein, T.
Clinical Cancer Research 19 (2): 320-326. 15 January 2013

2010

HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth.
Milde, T., Oehme, I., Korshunov, A., Kopp-Schneider, A., Remke, M., Northcott, P., Deubzer, H.E., Lodrini, M., Taylor, M.D., von Deimling, A., Pfister, S. and Witt, O.
Clinical Cancer Research 16 (12): 3240-3252. 15 June 2010

T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
Leisegang, M., Turqueti-Neves, A., Engels, B., Blankenstein, T., Schendel, D.J., Uckert, W. and Noessner, E.
Clinical Cancer Research 16 (8): 2333-2343. 15 April 2010

Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.
Hammer, S., Sommer, A., Fichtner, I., Becker, M., Rolff, J., Merk, J., Klar, U. and Hoffmann, J.
Clinical Cancer Research 16 (5): 1452-1465. 1 March 2010

2009

Histone deacetylase 8 in neuroblastoma tumorigenesis.
Oehme, I., Deubzer, H.E., Wegener, D., Pickert, D., Linke, J.P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S.M., von Deimling, A., Fischer, M. and Witt, O.
Clinical Cancer Research 15 (1): 91-99. January 2009

2008

Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer.
Walther, W., Siegel, R., Kobelt, D., Knoesel, T., Dietel, M., Bembenek, A., Aumann, J., Schleef, M., Baier, R., Stein, U. and Schlag, P.M.
Clinical Cancer Research 14 (22): 7545-7553. 15 November 2008

Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.
Michaelis, M., Bliss, J., Arnold, S.C., Hinsch, N., Rothweiler, F., Deubzer, H.E., Witt, O., Langer, K., Doerr, H.W., Wels, W.S. and Cinatl, J.
Clinical Cancer Research 14 (20): 6531-6537. 16 October 2008

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Fichtner, I., Rolff, J., Soong, R., Hoffmann, J., Hammer, S., Sommer, A., Becker, M. and Merk, J.
Clinical Cancer Research 14 (20): 6456-6468. 15 October 2008

2006

Author reply: Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors.
Wardelmann, E., Biermann, K., Merkelbach-Bruse, S., Thomas, N., Schildhaus, H.U., Heinicke, T., Speidel, N., Pietsch, T., Buettner, R., Pink, D., Reichardt, P. and Hohenberger, P.
Clinical Cancer Research 12 (20): 6206-6207. 15 October 2006

The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo.
Shalapour, S., Zelmer, A., Pfau, M., Moderegger, E., Costa-Blechschmidt, C., van Landeghem, F.K., Taube, T., Fichtner, I., Buehrer, C., Henze, G., Seeger, K. and Wellmann, S.
Clinical Cancer Research 12 (18): 5526-5532. 15 September 2006

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Wardelmann, E., Merkelbach-Bruse, S., Pauls, K., Thomas, N., Schildhaus, H.U., Heinicke, T., Speidel, N., Pietsch, T., Buettner, R., Pink, D., Reichardt, P. and Hohenberger, P.
Clinical Cancer Research 12 : 1743-1749. 15 March 2006

2005

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.
Lakhani, S.R., Reis-Filho, J.S., Fulford, L., Penault-Llorca, F., van der Vjiver, M., Parry, S., Bishop, T., Benitez, J., Rivas, C., Bignon, Y.J., Chang-Claude, J., Hamann, U., Cornelisse, C.J., Devilee, P., Beckmann, M.W., Nestle-Kramling, C., Daly, P.A., Haites, N., Varley, J., Lalloo, F., Evans, G., Maugard, C., Meijers-Heijboer, H., Klijn, J.G.M., Olah, E., Gusterson, B.A., Pilotti, S., Radice, P., Scherneck, S., Sobol, H., Jacquemier, J., Wagner, T., Peto, J., Stratton, M.R., McGuffog, L. and Easton, D.F.
Clinical Cancer Research 11 (14): 5175-5180. 15 July 2005

Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs.
Frankenberger, B., Pohla, H., Noessner, E., Willimsky, G., Papier, B., Pezzutto, A., Kopp, J., Oberneder, R., Blankenstein, T. and Schendel, D.J.
Clinical Cancer Research 11 : 1733-1742. 1 January 2005

2004

Pathology of ovarian cancers in BRCA1 and BRCA2 carriers.
Lakhani, S.R., Manek, S., Penault-Llorca, F., Flanagan, A., Arnout, L., Merrett, S., McGuffog, L., Steele, D., Devilee, P., Klijn, J.G., Meijers-Heijboer, H., Radice, P., Pilotti, S., Nevanlinna, H., Butzow, R., Sobol, H., Jacquemier, J., Lyonet, D.S., Neuhausen, S.L., Weber, B., Wagner, T., Winqvist, R., Bignon, Y.J., Monti, F., Schmitt, F., Lenoir, G., Seitz, S., Hamman, U., Pharoah, P., Lane, G., Ponder, B., Bishop, D.T. and Easton, D.F.
Clinical Cancer Research 10 (7): 2473-2481. 1 April 2004

2000

Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.
Tamm, I., Kornblau, S.M., Segall, H., Krajewski, S., Welsh, K., Kitada, S., Scudiero, D.A., Tudor, G., Qui, Y.H., Monks, A., Andreeff, M. and Reed, J.C.
Clinical Cancer Research 6 (5): 1796-1803. 1 May 2000

The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.
Lakhani, S.R., Gusterson, B.A., Jacquemier, J., Sloane, J.P., Anderson, T.J., Van de Vijver, M.J., Venter, D., Freeman, A., Antoniou, A., McGuffog, L., Smyth, E., Steel, C.M., Haites, N., Scott, R.J., Goldgar, D., Neuhausen, S., Daly, P.A., Ormiston, W., McManus, R., Scherneck, S., Ponder, B.A.J., Futreal, P.A., Peto, J., Stoppa-Lyonnet, D., Bignon, Y.J., Struewing, J.P., Bishop, D.T., Klijn, J.G.M., Devilee, P., Cornelisse, C.J., Lasset, C., Lenoir, G., Barkardottir, R.B., Egilsson, V., Hamann, U., Chang-Claude, J., Sobol, H., Weber, B., Easton, D.F. and Stratton, M.R.
Clinical Cancer Research 6 (3): 782-789. March 2000

1999

Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas.
Hoffmann, J., Schmidt-Peter, P., Haensch, W., Naundorf, H., Bunge, A., Becker, M. and Fichtner, I.
Clinical Cancer Research 5 : 2198-2204. 1 August 1999

1998

Antiangiogenic chemotherapeutic agents: Characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models1.
Schirner, M., Hoffmann, J., Menrad, A. and Schneider, M.R.
Clinical Cancer Research 4 : 1331-1336. 1 January 1998